{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T04:51:51Z","timestamp":1771303911598,"version":"3.50.1"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T00:00:00Z","timestamp":1738800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T00:00:00Z","timestamp":1738800000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1038\/s41375-025-02521-w","type":"journal-article","created":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T08:05:07Z","timestamp":1738829107000},"page":"775-778","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Correspondence to: \u201cCombination therapies with ponatinib and asciminib in a preclinical model of chronic myeloid leukemia blast crisis with compound mutations\u201d, Curik N et al. Leukemia. 2024; 38: 1415\u20131418"],"prefix":"10.1038","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2727-658X","authenticated-orcid":false,"given":"Seiichi","family":"Okabe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuya","family":"Arai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8608-4393","authenticated-orcid":false,"given":"Akihiko","family":"Gotoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,6]]},"reference":[{"key":"2521_CR1","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1038\/s41375-024-02248-0","volume":"38","author":"N Curik","year":"2024","unstructured":"Curik N, Laznicka A, Polivkova V, Krizkova J, Pokorna E, Semerak P, et al. Combination therapies with ponatinib and asciminib in a preclinical model of chronic myeloid leukemia blast crisis with compound mutations. Leukemia. 2024;38:1415\u20138.","journal-title":"Leukemia"},{"key":"2521_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2021.100825","volume":"49","author":"AEG Osman","year":"2021","unstructured":"Osman AEG, Deininger MW. Chronic myeloid leukemia: Modern therapies, current challenges and future directions. Blood Rev. 2021;49:100825.","journal-title":"Blood Rev"},{"key":"2521_CR3","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1002\/ajh.27443","volume":"99","author":"E Jabbour","year":"2024","unstructured":"Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring. Am J Hematol. 2024;99:2191\u2013212.","journal-title":"Am J Hematol"},{"key":"2521_CR4","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.hoc.2017.04.007","volume":"31","author":"AB Patel","year":"2017","unstructured":"Patel AB, O\u2019Hare T, Deininger MW. Mechanisms of resistance to ABL kinase inhibition in chronic myeloid leukemia and the development of next generation ABL kinase inhibitors. Hematol Oncol Clin North Am. 2017;31:589\u2013612.","journal-title":"Hematol Oncol Clin North Am"},{"key":"2521_CR5","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.ccr.2014.07.006","volume":"26","author":"MS Zabriskie","year":"2014","unstructured":"Zabriskie MS, Eide CA, Tantravahi SK, Vellore NA, Estrada J, Nicolini FE, et al. BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer Cell. 2014;26:428\u201342.","journal-title":"Cancer Cell"},{"key":"2521_CR6","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1016\/j.ccell.2024.08.004","volume":"42","author":"CA Eide","year":"2024","unstructured":"Eide CA, Brewer D, Xie T, Schultz AR, Savage SL, Muratcioglu S, et al. Overcoming clinical BCR-ABL1 compound mutant resistance with combined ponatinib and asciminib therapy. Cancer Cell. 2024;42:1486\u20138.","journal-title":"Cancer Cell"},{"key":"2521_CR7","doi-asserted-by":"publisher","first-page":"319","DOI":"10.14740\/wjon1818","volume":"15","author":"S Okabe","year":"2024","unstructured":"Okabe S, Moriyama M, Gotoh A. Characterization of asciminib-resistant Philadelphia chromosome-positive cells. World J Oncol. 2024;15:319\u201324.","journal-title":"World J Oncol"},{"key":"2521_CR8","doi-asserted-by":"publisher","first-page":"3086","DOI":"10.1182\/blood-2013-04-494773","volume":"122","author":"S Okabe","year":"2013","unstructured":"Okabe S, Tauchi T, Tanaka Y, Katagiri S, Kitahara T, Ohyashiki K. Activity of omacetaxine mepesuccinate against ponatinib-resistant BCR-ABL-positive cells. Blood. 2013;122:3086\u20138.","journal-title":"Blood"},{"key":"2521_CR9","doi-asserted-by":"publisher","first-page":"E9","DOI":"10.1002\/ajh.27095","volume":"99","author":"I Sponseiler","year":"2024","unstructured":"Sponseiler I, Bandian AM, Pusic P, Lion T. Combinatorial treatment options for highly resistant compound mutations in the kinase domain of the BCR::ABL1 fusion gene in Ph-positive leukemias. Am J Hematol. 2024;99:E9\u2013E11.","journal-title":"Am J Hematol"},{"key":"2521_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11037-8","volume":"10","author":"F Maura","year":"2019","unstructured":"Maura F, Degasperi A, Nadeu F, Leongamornlert D, Davies H, Moore L, et al. A practical guide for mutational signature analysis in hematological malignancies. Nat Commun. 2019;10:2969.","journal-title":"Nat Commun"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02521-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02521-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02521-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T16:04:42Z","timestamp":1741104282000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02521-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,6]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["2521"],"URL":"https:\/\/doi.org\/10.1038\/s41375-025-02521-w","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,6]]},"assertion":[{"value":"21 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.G. received research funding from Ono Pharmaceutical Co., Ltd.; Taiho Pharmaceutical Co., Ltd.; Chugai Pharmaceutical Co., Ltd.; Otsuka Pharmaceutical Co., Ltd.; and Asahi Kasei Co., Ltd. A.G. received honoraria from Novartis Pharma K.K.; Alexion Pharmaceuticals, Inc., Eisai Co., Ltd.; Ono Pharmaceutical Co., Ltd.; Taiho Pharmaceutical Co., Ltd.; Takeda Pharmaceutical Co., Ltd.; Nippon Shinyaku Co., Ltd.; Chugai Pharmaceutical Co., Ltd.; Otsuka Pharmaceutical Co., Ltd.; Sumitomo Pharma Co., Ltd.; Daiichi Sankyo Co., Ltd.; Nihon Pharmaceutical Co., Ltd.; Kyowa Kirin Co., Ltd.; Janssen Pharmaceutical K.K.; Pfizer Japan Inc.; Sanofi K.K. and Asahi Kasei. A.G. received consulting fees from PharmaEssentia Japan K.K.; Chugai Pharmaceutical Co., Ltd.; Alexion Pharmaceuticals, Inc and Asahi Kasei. In addition, A.G. participated in the data safety monitoring board or advisory board of PharmaEssentia Japan K.K.; Chugai Pharmaceutical Co., Ltd.; and Alexion Pharmaceuticals, Inc. S.O. and M.M. report no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}